Advertisement

Annals of Nuclear Medicine

, Volume 18, Issue 4, pp 345–349 | Cite as

Multifactorial analysis on the short-term side effects occurring within 96 hour after radioiodine-131 therapy for differentiated thyroid carcinoma

  • Tamotsu Kita
  • Kunihiko Yokoyama
  • Takahiro Higuchi
  • Seigo Kinuya
  • Junichi Taki
  • Kenichi Nakajima
  • Takatoshi Michigishi
  • Norihisa Tonami
Original Article

Abstract

Objective

This study was performed to clarify factors that might influence short-term side effects occurring within 96 hours after administration of131I for patients with thyroid carcinoma.Methods: In 71 patients with differentiated thyroid carcinoma, short-term side effects including gastrointestinal complaints, salivary gland swelling with pain, change in taste and headache were retrospectively analyzed. All patients were given domperidone for prevention of gastrointestinal complaints and advised to consume sour foods to promote discharge of radioiodine from the salivary glands. Selected factors possibly affecting the incidence of side effects were dose per body weight, TSH, effective half-life of131I, sex, age,131I accumulation into the stomach and salivary glands, and edema prior to radioiodine administration. The factors were evaluated by multivariate analyses.

Results

Incidence of gastrointestinal complaints, salivary gland swelling with pain, change in taste and headache was 65.2%, 50.0%, 9.8% and 4.4%, respectively. In gastrointestinal complaints, the incidence of appetite loss, nausea and vomiting was 60.9%, 40.2% and 7.6%, respectively. The gastrointestinal complaints increased significantly in the patients dosed above 55.5 MBq/kg and with TSH elevation. For salivary gland swelling with pain, female patients displayed a significantly higher incidence than males. No statistically significant factors were detected for change in taste or headache.

Conclusions

Significant factors influencing short-term side effects were dose per body weight and TSH values for gastrointestinal complaints, and female sex for salivary gland swelling with pain. Our preliminary experience suggests that the most frequent gastrointestinal complaints can be prevented with ramosetron.

Key words

radioiodine therapy thyroid cancer short-term side effects dose TSH 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Van Nostrand D, Neutze J, Atkins F. Side effects of “rational dose” iodine-131 therapy for metastatic well-differentiated thyroid carcinoma.J Nucl Med 1986; 27:1519–1527.PubMedGoogle Scholar
  2. 2.
    Lin W, Shen YY, Wang SJ. Short-term hazards of low-dose radioiodine ablation therapy in postsurgical thyroid cancer patients.Clin Nucl Med 1996; 21:780–782.PubMedCrossRefGoogle Scholar
  3. 3.
    Mazzaferri EL. Radioiodine and other treatments and outcome. In:Werner and Ingbar’s the Thyroid, Braverman L, Utiger RD (eds), Philadelphia; Lippincott-Raven Publishers, 1996: 922–945.Google Scholar
  4. 4.
    Zettinig G, Hanselmayer G, Fueger BJ, Hofmann A, Pirich C, Nepp J, et al. Long-term impairment of the lacrimal glands after radioiodine therapy: a cross-sectional study.Eur J Nucl Med 2002; 29:1428–1432.CrossRefGoogle Scholar
  5. 5.
    Bohuslavizki KH, Brenner W, Klutmann S, Hubner RH, Lassmann S, Feyerabend B, et al. Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy.J Nucl Med 1998; 39:1237–1242.PubMedGoogle Scholar
  6. 6.
    Solans R, Bosch JA, Galofre P, Porta F, Rosello J, Selva-O’Callagan A, et al. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy.J Nucl Med 2001; 42:738–743.PubMedGoogle Scholar
  7. 7.
    Alexander C, Bader JB, Schaefer A, Finke C, Kirsch CM. Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma.J Nucl Med 1998; 39:1551–1554.PubMedGoogle Scholar
  8. 8.
    Levy HA, Park CH. Effect of reserpine on salivary gland radioiodine uptake in thyroid cancer.Clin Nucl Med 1987; 12:303–307.PubMedCrossRefGoogle Scholar
  9. 9.
    Meier CA, Braverman LE, Ebner SA, Veronikis I, Daniels GH, Ross DS, et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study).J Clin Endcrinol Metab 1994; 78:188–196.CrossRefGoogle Scholar
  10. 10.
    Krausz Y, Uziely B, Nesher R, Chisin R, Glaser B. Recombinant thyroid-stimulating hormone in differentiated thyroid cancer.Isr Med Assoc 2001; 11:843–849.Google Scholar

Copyright information

© Springer 2004

Authors and Affiliations

  • Tamotsu Kita
    • 1
    • 2
  • Kunihiko Yokoyama
    • 1
  • Takahiro Higuchi
    • 2
  • Seigo Kinuya
    • 1
  • Junichi Taki
    • 1
  • Kenichi Nakajima
    • 1
  • Takatoshi Michigishi
    • 1
  • Norihisa Tonami
    • 1
  1. 1.Department of Biotracer MedicineKanazawa University Graduate School of Medical SciencesJapan
  2. 2.PET CenterKanazawa Cardiovascular HospitalJapan

Personalised recommendations